Sysmex (OTCMKTS:SSMXY) Issues FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.590-0.590 for the period. The company issued revenue guidance of $3.4 billion-$3.4 billion.

Sysmex Stock Performance

SSMXY traded up $0.88 during trading on Friday, hitting $19.71. 39,701 shares of the company traded hands, compared to its average volume of 52,427. The firm has a market cap of $12.40 billion, a P/E ratio of 37.16 and a beta of 0.84. Sysmex has a one year low of $14.38 and a one year high of $29.78. The company has a quick ratio of 2.40, a current ratio of 3.23 and a debt-to-equity ratio of 0.11. The stock’s fifty day moving average is $19.22 and its 200 day moving average is $17.60.

Sysmex (OTCMKTS:SSMXY) last issued its earnings results on Tuesday, August 6th. The company reported $0.11 earnings per share (EPS) for the quarter. The firm had revenue of $718.13 million during the quarter. As a group, equities analysts predict that Sysmex will post 0.57 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.